Evidence map›Paper›PMID 25789864›Full record

ArticlePloS one2015

Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.

Gustavo Ferrín, Manuel Rodríguez-Perálvarez, Patricia Aguilar-Melero, Isidora Ranchal, Camilo Llamoza, Clara I Linares, Sandra González-Rubio, Jordi Muntané, Javier Briceño, Pedro López-Cillero and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. DIGE Analysis Software and Protein Identification Approaches.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Gustavo FerrínMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain.
Manuel Rodríguez-PerálvarezMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain; Hepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
Patricia Aguilar-MeleroMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain.
Isidora RanchalMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain.
Camilo LlamozaHepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
Clara I LinaresMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain.
Sandra González-RubioMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain.
Jordi MuntanéMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain.
Javier BriceñoMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain; Hepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
Pedro López-CilleroMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain; Hepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
José Luis Montero-ÁlvarezMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain; Hepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
Manuel de la MataMaimónides Institute for Biomedical Research in Córdoba (IMBIC), Reina Sofía University Hospital, Córdoba, Spain; Biomedical Research Centre Network, Digestive and Liver Diseases (CIBERehd), Córdoba, Spain; Hepatology and Liver Transplantation Unit, Reina Sofía University Hospital, Córdoba, Spain.
Hospital Universitario Reina Sofía · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESCentre for Biomedical Network Research on Rare Diseases · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers in the world, with limited options for treatment unless timely diagnosed. Chronic hepatitis C virus (HCV) infection and persistent heavy alcohol consumption are independent risk factors for HCC development, which may induce a specific protein expression pattern different from those caused separately. The aim of the study was to identify protein biomarkers for the detection of HCC in HCV-infected alcoholic patients with cirrhosis in order to improve survival. We compared protein expression profiles of plasma samples from 52 HCV-infected alcoholic patients with and without HCC, using 2-D DIGE coupled with MALDI-TOF/TOF mass spectrometry. The 2-D DIGE results were analyzed statistically using Decyder software, and verified by western-blot and ELISA. In plasma samples from HCV-infected alcoholic patients, we found significantly differential expression profiles of carboxypeptidase-N, ceruloplasmin (CP), complement component 4a (C4a), fibrinogen-alpha (FGA), immunoglobulin mu chain C region, serum albumin, and serum paraoxonase/arylesterase 1 (PON1). Deregulation of plasma/serum levels of the identified proteins was associated to HCV, ethanol consumption, and/or HCC progression. In the validation through ELISA, C4a serum concentration was increased in HCC patients (2.4±1 ng/mg vs 1.8±0.6 ng/mg; p = 0.029), being the only independent predictor of HCC in the multivariate analysis (OR = 2.15; p = 0.015), with an AUROC = 0.70. The combination of C4a, FGA, CP and PON1 improved slightly the predictive ability of C4a alone (AUROC 0.81). In conclusion, we identified proteins related to acute-phase response, oxidative stress, or immune response, whose differential expression in plasma may be attributed to the presence of HCC. Among them, C4a, and its combination with CP, FGA and PON1, could be considered as potentially reliable biomarkers for the detection of HCC in HCV-infected alcoholic patients.

Indexed as

AlcoholismBiomarkers, TumorBlotting, WesternCarcinoma, HepatocellularEnzyme-Linked Immunosorbent AssayHepatitis CHumansLiver CirrhosisLiver NeoplasmsSoftwareBiomarkers, Tumor

Identifiers

PMID25789864
PMCPMC4366144
OpenAlexW2082313666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.